Profound Opioid and Medetomidine Withdrawal: A Case Series and Narrative Review of Available Literature

  1. Elise Paquin
  2. Gamal Fitzpatrick
  3. Dennis Goodstein
  4. Drew Lockstein
  5. Jamal Rashid
  6. TaReva Warrick-Stone
  7. Oluwarotimi Vaughan-Ogunlusi
  8. Maeve Montesi
  9. Sejal Patel
  10. Kelly Goodsell
  11. Christopher Martin
  12. Keira Chism
  13. Phil Durney
  14. Jennifer L. Kahoud
  15. Kory London
0 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Medetomidine, a potent veterinary α-2 agonist, has emerged as a fentanyl adulterant in the non-medical opioid supply. Its use has been linked to a novel withdrawal syndrome that is often resistant to conventional treatment protocols. Four cases are presented demonstrating extreme forms of this withdrawal syndrome. A literature review is provided showing both the paucity of available literature as well as potential avenues for treatment and future research. As adulterants continue to proliferate in the illicit drug supply, clinicians should anticipate atypical withdrawal phenotypes and consider early aggressive intervention.

Related articles

Related articles are currently not available for this article.